Mortality in acute pancreatitis with persistent organ failure is determined by the number, type, and sequence of organ systems affected.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
03 2021
Historique:
received: 13 10 2020
accepted: 23 12 2020
entrez: 19 4 2021
pubmed: 20 4 2021
medline: 28 12 2021
Statut: ppublish

Résumé

Persistent organ failure (POF) is the strongest determinant of mortality in acute pancreatitis (AP). There is a paucity of data regarding the impact of different POF attributes on mortality and the role of different characteristics of systemic inflammatory response syndrome (SIRS) in the risk of developing POF. We aimed to assess the association of POF dynamic features with mortality and SIRS characteristics with POF. We studied 1544 AP subjects prospectively enrolled at 22 international centers (APPRENTICE consortium). First, we estimated the association of onset, duration, and maximal score of SIRS with POF. Then, we evaluated the risk of mortality based on POF onset, duration, number, type, and sequence of organs affected. Analyses were adjusted for potential confounders. 58% had SIRS, 11% developed POF, and 2.5% died. Early SIRS, persistent SIRS, and maximal SIRS score ≥ 3 were independently associated with higher risk of POF (p < 0.05). Mortality risk in POF was higher with two (33%, odds ratio [OR] = 10.8, 3.3-34.9) and three (48%, OR = 20.2, 5.9-68.6) organs failing, in comparison to single POF (4%). In subjects with multiple POF, mortality was higher when the cardiovascular and respiratory systems failed first or concurrently as compared to when the renal system failed first or concurrently with other organ (p < 0.05). In multivariate regression model, the number and sequence of organs affected in POF were associated with mortality (p < 0.05). Onset and duration of POF had no impact mortality. In AP patients with POF, the risk of mortality is influenced by the number, type, and sequence of organs affected. These results are useful for future revisions of AP severity classification systems.

Sections du résumé

BACKGROUND
Persistent organ failure (POF) is the strongest determinant of mortality in acute pancreatitis (AP). There is a paucity of data regarding the impact of different POF attributes on mortality and the role of different characteristics of systemic inflammatory response syndrome (SIRS) in the risk of developing POF.
OBJECTIVE
We aimed to assess the association of POF dynamic features with mortality and SIRS characteristics with POF.
METHODS
We studied 1544 AP subjects prospectively enrolled at 22 international centers (APPRENTICE consortium). First, we estimated the association of onset, duration, and maximal score of SIRS with POF. Then, we evaluated the risk of mortality based on POF onset, duration, number, type, and sequence of organs affected. Analyses were adjusted for potential confounders.
RESULTS
58% had SIRS, 11% developed POF, and 2.5% died. Early SIRS, persistent SIRS, and maximal SIRS score ≥ 3 were independently associated with higher risk of POF (p < 0.05). Mortality risk in POF was higher with two (33%, odds ratio [OR] = 10.8, 3.3-34.9) and three (48%, OR = 20.2, 5.9-68.6) organs failing, in comparison to single POF (4%). In subjects with multiple POF, mortality was higher when the cardiovascular and respiratory systems failed first or concurrently as compared to when the renal system failed first or concurrently with other organ (p < 0.05). In multivariate regression model, the number and sequence of organs affected in POF were associated with mortality (p < 0.05). Onset and duration of POF had no impact mortality.
CONCLUSION
In AP patients with POF, the risk of mortality is influenced by the number, type, and sequence of organs affected. These results are useful for future revisions of AP severity classification systems.

Identifiants

pubmed: 33871926
doi: 10.1002/ueg2.12057
pmc: PMC8259236
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-149

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States

Informations de copyright

© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.

Références

Gut. 2013 Jan;62(1):102-11
pubmed: 23100216
JOP. 2013 Sep 10;14(5):475-83
pubmed: 24018592
Crit Care Med. 1995 Oct;23(10):1638-52
pubmed: 7587228
World J Gastroenterol. 2017 Aug 7;23(29):5431-5437
pubmed: 28839444
Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416
pubmed: 23896955
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
N Engl J Med. 2010 Apr 22;362(16):1491-502
pubmed: 20410514
Pancreas. 2014 Nov;43(8):1244-8
pubmed: 25084001
Pancreas. 2018 Mar;47(3):302-307
pubmed: 29401171
Pancreatology. 2018 Dec;18(8):870-877
pubmed: 30337224
HPB (Oxford). 2007;9(6):414-20
pubmed: 18345287
Ann Gastroenterol. 2017;30(1):106-113
pubmed: 28042246
Clin Gastroenterol Hepatol. 2009 Nov;7(11):1247-51
pubmed: 19686869
J Natl Med Assoc. 2007 Dec;99(12):1402-6
pubmed: 18229777
Gut. 2019 Jun;68(6):1044-1051
pubmed: 29950344
Gastroenterology. 2012 Jun;142(7):1476-82; quiz e15-6
pubmed: 22425589
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1567-1575.e2
pubmed: 31712075
Ann Surg. 2019 Aug;270(2):348-355
pubmed: 29672416
HPB (Oxford). 2017 Jan;19(1):21-28
pubmed: 27887788
J Biomed Inform. 2014 Apr;48:106-13
pubmed: 24361388
Ann Surg. 2012 Dec;256(6):875-80
pubmed: 22735715
Gastroenterology. 2010 Sep;139(3):813-20
pubmed: 20540942
Ann Intern Med. 2016 Oct 4;165(7):482-490
pubmed: 27454310
Pancreas. 2008 Apr;36(3):249-54
pubmed: 18362837
Gut. 2020 Mar;69(3):604-605
pubmed: 31233394
Br J Surg. 2006 Jun;93(6):738-44
pubmed: 16671062
Pancreas. 2016 Jan;45(1):e5-7
pubmed: 26658047
Pancreatology. 2016 Jul-Aug;16(4):542-50
pubmed: 27161172
HPB (Oxford). 2013 Jul;15(7):523-8
pubmed: 23750495
Br J Surg. 2002 Mar;89(3):298-302
pubmed: 11872053
Am J Gastroenterol. 2007 Dec;102(12):2688-95
pubmed: 17662103
Gut. 2004 Sep;53(9):1340-4
pubmed: 15306596

Auteurs

Jorge D Machicado (JD)

Mayo Clinic Heath System, Eau Claire, Wisconsin, USA.

Amir Gougol (A)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Xiaoqing Tan (X)

Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Xiaotian Gao (X)

Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Pedram Paragomi (P)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Ioannis Pothoulakis (I)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Rupjyoti Talukdar (R)

Asian Gastroenterology Institute, Hyderabad, India.

Rakesh Kochhar (R)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Mahesh K Goenka (MK)

Apollo Gleneagles Hospitals Kolkata, Kolkata, India.

Aiste Gulla (A)

Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Georgetown University Hospital, Washington DC, USA.

Jose A Gonzalez (JA)

Universidad Autónoma de Nueva León, Monterrey, Mexico.

Vikesh K Singh (VK)

Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Miguel Ferreira (M)

Hospital Nacional de Itauguá, Itaugua, Paraguay.

Tyler Stevens (T)

Cleveland Clinic, Cleveland, Ohio, USA.

Sorin T Barbu (ST)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Haq Nawaz (H)

Eastern Maine Medical Center, Bangor, Maine, USA.

Silvia C Gutierrez (SC)

Hospital Nacional "Profesor Alejandro Posadas", Buenos Aires, Argentina.

Narcis O Zarnescu (NO)

"Carol Davila" University of Medicine and Pharmacy, University Emergency Hospital, Bucharest, Romania.

Gabriele Capurso (G)

San Raffaele Scientific Institute (IRCCS), Vita Salute San Raffaele University, Milan, Italy.
Andrea Hospital, Rome, Italy.

Jeffrey J Easler (JJ)

Indiana University School of Medicine, Indianapolis, Indiana, USA.

Konstantinos Triantafyllou (K)

Attikon University General Hospital, Athens, Greece.

Mario Pelaez-Luna (M)

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán-Universidad Autónoma de Mexico, Mexico City, Mexico.

Shyam Thakkar (S)

Allegheny Health Network, Pittsburgh, Pennsylvania, USA.

Carlos Ocampo (C)

Hospital General de Argudos "Dr. Cosme Argerich", Buenos Aires, Argentina.

Enrique de-Madaria (E)

Gastroenterology Department, Alicante University General Hospital, ISABIAL, Alicante, Spain.

Gregory A Cote (GA)

Medical University of South Carolina, Charleston, South Carolina, USA.

Bechien U Wu (BU)

Kaiser Permanente, Los Angeles, California, USA.

Darwin L Conwell (DL)

The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Phil A Hart (PA)

The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Gong Tang (G)

Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Georgios I Papachristou (GI)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH